Navigation auf uzh.ch
With the advent of clinically effective immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the University of Zurich, antibody-based regenerative therapies are being developed toward clinical applications. Aducanumab removes beta-amyloid plaques from brains of patients with Alzheimer's disease, followed by stabilization of cognitive and functional abilities. In addition to cell-based therapies and tissue replacement, antibody-based therapies designed to enable endogenous regeneration are becoming an important addition to the therapeutic tool kit in regenerative medicine (Nature. September 1, 2016. doi:10.1038/nature19323).
Translational Alzheimer imaging biomarker development (Dr. Ruiqing Ni, Group Leader)
Cellular Neurobiology (Dr. Uwe Konietzko, Scientific Head of Division and Group Leader)
Translational Neurodegeneration (PD Dr. Christian Tackenberg, Head of Stem Cell Research and Group Leader)
Immunology of Neurodegeneration (Dr. Christoph Gericke, Group Leader)
Cell Therapy for Brain Regeneration (Dr. Ruslan Rust, Group Leader)